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Introduction: Biomarkers may prove to be valuable tools to man-
age those at risk of lung cancer. Sputum analysis using DNA
cytometry has shown promise, but an automated, objective sputum
analysis test has yet to be developed. This study evaluated the
performance characteristics of the LungSign test for lung cancer and
compared them to conventional cytology
Methods: A multicenter validation trial was conducted in which
sputum specimens were prospectively collected from subjects sus-
pected of having lung cancer during diagnostic workup. Specimens
were placed on slides, DNA stained using Feulgen thionin, and
analyzed using an automated cytometry-based scoring system.
Smears were also prepared from the sputum specimens, stained by
the Papanicolaou procedure, and analyzed using conventional cytol-
ogy. LungSign scores and conventional cytology results were com-
pared with the subject diagnoses.
Results: A total of 1235 high-risk subjects were enrolled at nine
clinical sites. Of 1123 subjects included for analysis, 370 were found
to have lung cancer—a 33% prevalence. The a priori selected
LungSign score threshold detected 40% of all lung cancers and 35%
of stage I lung cancers with 91% specificity. Test performance was
statistically equivalent across cancer stages, histologic types, and
localizations for 330 analyzable lung cancer subjects. LungSign
receiver operating characteristic area under the curve measure for
the test was 0.692. Conventional cytology detected 16% of lung
cancers with 99% specificity.
Conclusions: DNA cytometry of sputum using the LungSign test
detects stage I lung cancer and may provide a new tool to manage
high-risk individuals.
Key Words: Early diagnosis, Lung neoplasms, Image cytometry,
Cytology.
(J Thorac Oncol. 2007;2: 993–1000)
The creation of effective early detection programs repre-sents an important step in reducing lung cancer mortali-
ty.1,2 Such programs will likely use bronchoscopy and com-
puted tomography (CT), technologies that serve as both
cancer detection and localization tools. However, questions
remain as how to best identify high-risk individuals suitable
for screening and how to manage those who receive equivo-
cal screen results. Lung cancer biomarkers in serum, breath,
and sputum may provide independent information to the
clinician and assist in patient management.3
Quantitative image analysis of sputum through DNA
cytometry4 is a biomarker approach that allows measurement
of cell properties not obvious to the pathologist. It is a
powerful alternative to conventional cytology. By measuring
the DNA content of cells (ploidy), image analysis detects
large-scale chromosomal abnormalities associated with ma-
lignancy. Normal epithelial cells in sputum consist mostly of
resting (diploid) cells with a DNA index of 1.0, and small
fractions of proliferating and polyploidy cells. The observa-
tion of a significant fraction of hyperdiploid cells in sputum
is atypical and may represent the presence of a DNA aneu-
ploid5 cell line. The detection of DNA aneuploidy has diag-
nostic and prognostic significance in various cancers,6 includ-
ing lung cancer.7
Beyond measuring DNA aneuploidy, systematic
changes to diploid and near-diploid cells in the presence of
malignancy can also detect cancer. Cell variations indicative
of cancer, termed malignancy associated changes (MACs) by
Nieburgs et al.,8–10 can be observed through examination of
the chromatin distribution within the cell nuclei of ostensibly
normal cells under light microscopy.11 Detection of malig-
nancy through measuring MAC effects has been success-
fully applied to tissues such as uterine cervix,12,13 colon,14
breast,15and lung.16,17
Sputum cytometry systems based on aneuploidy, MAC,
or a combination of the two have the potential to bring
practical, effective systems for the detection of early lung
cancer into clinical practice. Three groups have recently
published results18–20 of clinical studies of semiautomated
sputum analysis systems designed to detect lung malignancy.
All three used DNA image cytometry of Feulgen thionin–
stained sputum slides, followed by expert review of the cell
nuclear galleries by cytotechnologists.
This paper describes the validation trial for the Lung-
Sign test, a fully automated sputum test for lung cancer.
LungSign is an image cytometry system for analysis of
Feulgen thionin–stained21 sputum slides. The system auto-
matically scans slides and images thousands of cell nuclei per
slide, eliminating the need for time-consuming, subjective
review by cytotechnologists. It measures cell nuclear features
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and generates a single score for each specimen. The specimen
scoring function uses a 13-feature linear discriminant func-
tion incorporating seven statistical measures of properties of
diploid and near-diploid cells (MAC features) and six of
hyperdiploid cells. Feature selection and weight estimation
was performed using a set of preclinical data collected before
2003. The preclinical results22 suggested that the test could
achieve nearly 50% sensitivity for stage I lung cancer at 90%
specificity.
PATIENTS AND METHODS
The validation trial was designed to evaluate the ability
of LungSign to detect lung cancer as compared with standard
clinical workup for patients suspected of having lung cancer.
Patient accrual began in March 2003 with three clinical
centers. Additional centers joined during the trial for a total of
nine sites enrolling subjects and collecting specimens by the
time accrual ended in September 2004.
The target population was patients referred for evalua-
tion of the presence of lung cancer based on their medical
history and clinical symptoms. Subjects were eligible for
inclusion in the study if they met all of the following criteria:
male/female aged 40 years or older; suspected of having lung
cancer based on symptoms or radiographic abnormality;
about to undergo more extensive diagnostic tests such as
bronchoscopy, CT scan, fine-needle aspiration biopsy, sur-
gery, etc.; capable of undergoing sputum induction.
Subjects were excluded if they were unable to cough
due to chest pain, had unstable angina, or had received
radiation therapy to the chest or systemic chemotherapy in
past 6 months.
The recruitment goal was 200 analyzable sputum spec-
imens from subjects confirmed to have lung cancer. This
number was selected to set an acceptable standard error for
the sensitivity values measured for the test. Similarly, a
recruitment goal of 800 analyzable sputum specimens was set
on the number of negative specimens to address test speci-
ficity estimates.
Review of the clinical protocol was completed by
Institutional Review Board Services of Canada, and approval
for investigational testing of the device was obtained from the
Health Canada Therapeutic Products Directorate. Each clin-
ical site obtained approval of the protocol from their local
ethics review board.
Sputum specimens were collected prospectively from
subjects undergoing diagnostic investigations for lung cancer.
Informed consent was obtained from each subject. Specimens
were collected through induction with an ultrasonic nebulizer
using 3% hypertonic saline. The procedure was conducted for
15 to 30 minutes depending on the patient’s ability to produce
sputum. Most induction procedures required less than 15
minutes and 99% required less than 30 minutes. No adverse
events were reported during the trial. Sputum specimens were
collected in specimen collection jars into which 25 ml of
cytologic fixative was added. Specimens were refrigerated at
4°C for an allowed maximum of 8 days before either pro-
cessing or shipping.
Specimens were processed to slides either at the clinical
site according to the study protocol or at the Perceptronix
laboratory in Vancouver, Canada. Slides were prepared at
four sites (Slovenia, United Kingdom, Korea, Russia), and
the others couriered liquid specimens directly to Vancouver.
Mucolysis of the specimens was performed chemically using
dithiothreitol and a mechanical shaker. A total of five slides
were prepared from each specimen. Two smears were created
for conventional cytological analysis, and three cytospin
slides were prepared for LungSign analysis. The slides were
allowed to air dry overnight before being shipped to Vancou-
ver for staining.
The staining and analysis of all slides were done in
Vancouver. Smears were stained using the Papanicolaou
procedure, and cytospin slides were stained using Feulgen
thionin. Slides were given blinded barcodes to ensure no
linkage could be made between the results of LungSign and
cytologic analysis during the course of the trial.
Site investigators established the reference diagnoses
for all subjects in the trial. Each subject classified as negative
had a minimum of 3 months of diagnostic follow-up. Clinical
investigators submitted case report forms that included pa-
tient demographic data and relevant information used to
determine the subjects’ lung cancer status. These reports were
held by the trial monitor; study personnel were blinded as to
the diagnostic outcomes of the patients until the conclusion of
the trial.
Conventional smears were analyzed by a cytotechnol-
ogist and then by an experienced pathologist from the British
Columbia Cancer Agency, who made the final determination
for each case. Slides were graded into six categories: normal,
benign, mild dysplasia, moderate dysplasia, severe dysplasia,
or carcinoma present. A grading of severe dysplasia or higher
was treated as positive by cytology in the analysis in the
results section. The adequacy criterion for conventional cy-
tology was the presence of alveolar macrophages.
Feulgen thionin–stained slides were scanned using an
automated image cytometer (AcCell-Savant, Molecular Di-
agnostics Inc., Chicago, IL) to collect images of cell nuclei
for analysis. A decision tree automatically categorized all
imaged objects according to a set of photometric, morpho-
metric, and texture features.23 Epithelial cell nuclei were
collected and specimens were considered scorable if at least
400 nuclei were imaged. A score threshold of 5.0, which had
corresponded to 90% specificity for the preclinical data, was
used to identify specimens as suspicious for lung cancer.
The performance of LungSign was analyzed for the
study threshold and compared with conventional cytology.
Receiver operating characteristic (ROC) analysis was per-
formed to examine the test performance for other score
thresholds. Lung cancer sensitivities were broken down by
cancer stage, histology, and localization. Binomial confi-
dence limits were calculated by the Clopper-Pearson method.
Tests of independence for contingency tables were conducted
using the Fisher exact test. ROC area under the curve (AUC)
was calculated by the trapezoidal rule and the variance
estimate of the ROC AUC was estimated by the method of
Delong et al.24
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RESULTS
A total of 1235 subjects were enrolled in the study from
nine sites (Table 1). From this total, 112 were excluded from
the final analysis. The reasons for exclusion were primarily
the presence of other cancers (34 subjects), lack of final
diagnosis by site investigators (31), and chemo/radiation
treatment before induction (20). Of 1123 subjects included
for analysis, 370 were diagnosed with lung cancer (33%).
This prevalence was significantly higher than the expected
prevalence of 20% to 25%. Figure 1 shows the flow of
subjects from enrollment to the result of their diagnostic
workups. Included subjects were predominantly male (69%)
and were primarily current or former smokers (82%), as
shown in Table 2. Among those with a smoking history, both
lung cancer positives and negatives tended to be heavy
smokers, with a median of 40 and 33 pack-years, respec-
tively. There were no explicit smoking or minimum pack-
year inclusion requirements in the trial. Despite this, both
positives and negatives consisted mostly of smokers with a
significant smoking history.
The TNM stage, histologic type, and localization of the
tumors are presented in Table 3. Early-stage cases repre-
sented a significant fraction of the total number of cancers
with stage I comprising 30% of tumors. Because only one
stage 0 was diagnosed, it is included with stage I for subse-
quent analysis. Squamous cell carcinoma (SCC) and adeno-
carcinoma were the dominant histologic types, representing
39% and 33% of the cancers, respectively. There was an
approximately even mix of central and peripheral tumors
(41% and 51%, respectively). Adenocarcinoma was signifi-
cantly more common (p  0.0001) for peripheral cancers
than for central ones, representing 44% and 19% of each
localization, respectively.
Figure 2 shows the overall ROC performance of Lung-
Sign in the validation trial. The study threshold of 5.0 resulted
in an empirical specificity of 91% (95% confidence interval
[CI]: 89%–93%) and sensitivity of 40% (95% CI: 35%–
46%). A more general measure of diagnostic performance,
the ROC AUC, was found to be 0.692 (95% CI: 0.655–
0.729). The ROC curve is skewed to toward higher specific-
ities, suggesting that the test does better at identifying sub-
jects at higher risk of lung cancer than for assuring negativity.
This is directly illustrated in Figure 3, which shows the
positive likelihood ratio (LR) and negative likelihood ratio
(LR) as functions of score threshold. These curves show
how the LungSign test result modifies the subject’s odds of
TABLE 1. Clinical Sites in the Validation Trial
Country No. of subjects enrolled
Slovenia 464
Russia 265
United Kingdom 226
Canada 110
Korea 101
Spain 28
United States 24
Austria 12
The Netherlands 5
FIGURE 1. Breakdown of partici-
pants by inclusion, specimen ade-
quacy and diagnostic workup.
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harboring lung cancer. The LR (Figure 3A) for a score
threshold of 5.0 is 4.5 (95% CI: 3.4–6.0), increasing further
with higher thresholds. In contrast, the lowest LR (Figure
3B) is 0.41 (95% CI: 0.2–0.8), meaning that a negative test
result corresponded with a reduction in the subject’s odds of
disease by around a factor of two.
Whereas different thresholds can be used with Lung-
Sign, conventional cytology records the observance of cellu-
lar atypia in the specimen. Its performance is therefore
represented by a single point in the ROC graph. The sensi-
tivity of conventional cytology was 16% (95% CI: 11%–
22%) with a specificity of 99.1% (95% CI: 97.6%–99.7%),
which corresponds with an LR of 17.2 (95% CI: 6.5–46.0).
LungSign sensitivity is similar to conventional cytology at a
correspondingly high specificity (Figure 2). For the subset of
specimens (npos  194, nneg  383) analyzable by both
methods, combining results using the logical odds ratio in-
creased the LungSign sensitivity from 37.1% to 42.3% while
decreasing specificity slightly from 94.3% to 93.5%.
The difference in adequacy criteria between Lung-
Sign and cytology led to significant differences in the
adequacy rates observed in the trial. Whereas LungSign
requires 400 analyzable cells, cytology required the pres-
ence of macrophages as evidence of a deep cough. Sputum
specimens contained a median of 4500 cells (range,
0 –10,000) and the inadequacy rate of specimens for Lung-
Sign analysis was 12% (95% CI: 10%–14%). The cytology
inadequacy rate was the same for negative and lung cancer
specimens at 43% (95% CI: 40%– 45%) and was signifi-
cantly higher than that of LungSign. Although nearly half
of the sputum specimens were cytology inadequate, Lung-
Sign diagnostic performance was not statistically lower for
these specimens (p  0.195). LungSign ROC AUC for
specimens considered adequate by conventional cytology
was 0.71 (95% CI: 0.67– 0.76), while LungSign ROC AUC
for cytology-inadequate specimens was 0.66 (95% CI:
0.60 – 0.72). Similarly, no statistical difference in ROC
AUC was seen for sites that prepared sputum slides versus
those that sent liquid specimens for analysis (p  0.567).
Table 4 shows the sensitivity by stage for LungSign
using the study threshold and for conventional cytology. The
number of positive subjects available for analysis by Lung-
Sign was higher because slides inadequate for cytology are
often scorable by LungSign. The specimen scoring function
was developed using a preclinical data set with positive cases
that consisted predominantly of specimens from stage I can-
TABLE 2. Subject Demographic Information
Positive subjects Negative subjects Total
No. of included subjects 370 753 1123
Age, yr, median (range) 65 (41–87) 62 (29–87) 63 (29–87)
Gender, % males 74 67 69
% of Current/former smokers 90 78 82
Pack-years for former and current
smokers, median (range)
40 (1–150) 33 (1–244) 36 (1–244)
TABLE 3. Cancer Distribution by Stage, Histology, and Localization
Stage No. (%) Tumor type No. (%) Localization No. (%)
0 1 (0) Squamous 146 (39) Central 150 (41)
I 112 (30) Adenocarcinoma 121 (33) Peripheral 190 (51)
II 54 (15) Small cell 35 (9) Not specified 30 (8)
III 106 (29) Large cell 13 (4) Total 370
IV 79 (21) Other 43 (12)
Not specified 18 (5) Not specified 12 (3)
Total 370 Total 370
FIGURE 2. Receiver operating characteristic curve for Lung-
Sign and performance of conventional cytology (circle) for
specimens adequate for analysis by each method. Sensitivity
and specificity standard errors bars representing 1 SD (1)
are shown.
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cers. It was anticipated that this would yield a function the
sensitivity of which was relatively independent of tumor
stage. It can be seen that for the study threshold, LungSign
was as sensitive for early-stage as late-stage cancers, with no
statistically significant difference in sensitivity among tumor
stages (p  0.49). Conventional cytology sensitivity varied
between 12% and 20%. There was no statistically significant
difference in sensitivity of adequate specimens observed for
conventional cytology (p  0.59).
The LungSign sensitivity by histology varied between
33% for adenocarcinoma and 52% for small-cell cancer
(Table 5). However, there was no statistically significant
difference in sensitivity for the LungSign study threshold
among the histologic classes (p  0.32). This was not the
case for conventional cytology, in which a difference in
sensitivity among histologic classes was observed (p 
0.015), attributed to the low sensitivity (5%) observed for
adenocarcinoma. Both detection approaches had slightly
higher sensitivities for central lesions versus peripheral ones,
but the differences are not statistically significant for either
LungSign (p 0.40) or for conventional cytology (p 0.33).
To investigate the performance of LungSign for alter-
native score thresholds, ROC analysis was performed. Figure
4A shows the ROC performance of the test for stage 0/I
versus stage II lung cancer. The ROC curves are compara-
ble over the range of possible score thresholds. The cumula-
tive distributions of scores for stage 0/I and stage II lung
cancer specimens exhibit no statistically significant differ-
ence (p  0.38 using the two-sample Kolmogorov-Smirnov
test). The performance of conventional cytology is also
shown on the figure.
Figure 4B shows the ROC performance of LungSign
for SCC versus adenocarcinoma, the two dominant histologic
types. Figure 4C shows the ROC performance for lesions
designated as central versus peripheral. Both pairs of ROC
curves are comparable, and the cumulative score distributions
show no significant statistical difference using the two-sam-
ple Kolmogorov-Smirnov test (p  0.79 and P  0.80,
respectively). As before conventional cytology performances
are shown. The discrepancy in the sensitivity of conventional
cytology for adenocarcinoma versus SCC appears notably in
this figure.
DISCUSSION
The purpose of the validation trial was to establish
LungSign performance characteristics for lung cancer detec-
tion in a very high risk population. The ROC curve in Figure
2 shows that the test provides significant discrimination for
lung cancers over a wide range of score thresholds. The a
priori threshold evaluated in the trial provided 40% sensitiv-
ity and 91% specificity overall, corresponding to a 4.5-fold
TABLE 4. Test Sensitivity Results by Cancer Stage for Adequate Specimens
LungSign at 91% specificity Conventional cytology
Score >5 Total positive subjects Sensitivity (95% CI) Cytology positive Total positive subjects Sensitivity (95% CI)
0/I 35 100 35% (26–45) 8 69 12% (5–22)
II 21 51 41% (28–56) 5 33 15% (5–32)
III 35 92 38% (28–49) 12 60 20% (11–32)
IV 33 71 46% (35–59) 5 40 13% (4–27)
Cancer cases with unspecified staging are not shown.
FIGURE 3. LungSign positive likelihood ratio (A) and nega-
tive likelihood ratio (B).
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increase in the odds of lung cancer. Test sensitivity for early
versus later stage disease (Figure 4A) was statistically
equivalent over the whole ROC curve. We believe that this
results from the LungSign development process, where
135 of 280 preclinical specimens used to develop the
scoring function were stage I cancer. Because the obser-
vation of DNA aneuploidy is less common in specimens
from stage I lung cancer, the test is primarily a MAC
detector; systematic changes to the nuclear conformation
of surrounding cells occur early in the development of the
cancerous lesion and are detectable through its progression.
Although previous DNA cytometry studies have shown
increasing levels of DNA aneuploidy in later stage cancers,
this was not observed in the LungSign trial. Xing et al.20
observed an increase in the rate of 5c-ploidy exceeding cells
with lung cancer stage. In our study, only 26 of the 330 lung
cancer specimens contained any 5c exceeding cells, and there
was no significant statistical difference in their frequency
across stages. The sensitivity of the hyperdiploidy compo-
nents and MAC components of the LungSign score did not
vary by cancer stage.
Although the presence of severe dysplasia in sputum is
highly indicative of lung cancer, it is not necessarily diag-
nostic.25 Nonetheless, it was decisive in that it provided a
high positive likelihood multiplier, albeit with low sensitivity.
In a clinical context, both decisiveness and sensitivity are
desirable; consider that even a test that produces no false-
positive results may not be accepted if the number of cancers
detected does not justify the cost. There is a tradeoff between
being able to detect enough cancers while maintaining the
decisiveness of the test outcome. An advantage of a contin-
uous test is that it may be optimized for this tradeoff by
adjusting the score threshold.
Although conventional cytology had a lower sensitivity
for adenocarcinoma, LungSign did not demonstrate a sensi-
tivity difference based on histologic type. This may be due to
the design methodology used in the development of the test.
The specimen scoring function was designed to detect
changes indicative of all histologic types of lung malignancy
with the least complexity (i.e., least number of parameters).
Nuclear chromatin features that may be good predictors of a
particular histologic type of malignancy may have been
excluded in favor of predictors that are associated with
malignancy in general. The design decision to use a single
function to detect malignancy rather than scoring functions
for each histologic type was based on the number of lung
cancer cases available to train the system.
A simple cytometric model for lung cancer detection
has less ability to represent the differences between negatives
and lung cancers, but is also less prone to overfit and is likely
to be more generalizable to new patient populations. In the
future, it may be possible to develop separate classifiers for
different cancer types. Because SCC tends to be centrally
located and adenocarcinoma tends to be peripheral, histolo-
gy-specific classifiers could provide additional information
about the location of potential malignancy. LungSign showed
no significant sensitivity difference for central versus periph-
eral localizations of lesions. It was expected that cytology
would be twice as sensitive for central lesions,26 and although
sensitivity was higher for central versus peripheral lesions
(19% versus 14%), the difference was not great enough to be
statistically significant.
The prevalence of lung cancer in the trial was 33%,
which was higher than expected and higher than that studied
in the recent DNA cytometry studies. The high prevalence
appears to reflect the referral practices at the institutions that
participated in the trial. Several of the physicians in the study
specialize in dealing with patients who are likely to have lung
cancer and received referrals of suspected cases from other
physicians. These patients typically had other forms of lung
disease, and Figure 2 therefore represents the ROC for Lung-
Sign applied in a differential diagnosis context.
The cytology inadequacy rate ranged from 20% in
Kelowna to 65% in Korea, averaging 43% overall. This is
high given that other studies have reported inadequacy rates
25%.27–29 The reason for the high inadequacy rate is not
known. All sites followed the same induction protocol and
used the same equipment. Sites that were less experienced
with sputum induction tended to have higher inadequacy
rates, but the inadequacy rates for all sites other than
Kelowna exceeded 30%.
Although the presence of macrophages ensures that a
sputum specimen derives from the lower respiratory tract, the
premise of the design of the LungSign test was that subtle
TABLE 5. Test Sensitivity Results by Type and Localization for Adequate Specimens
LungSign at 91% specificity Conventional cytology
Score >5 Total positive subjects Sensitivity (95% CI) Cytology positive Total positive subjects Sensitivity (95% CI)
Histology
Adenocarcinoma 38 114 33% (25–43) 3 66 5% (1–13)
Small cell 14 27 52% (32–71) 4 18 22% (6–48)
Squamous 52 128 41% (32–0) 18 86 21% (13–31)
Other 20 51 39% (26–54) 6 35 17% (7–34)
Localization
Central 53 131 40% (32–49) 17 91 19% (11–28)
Peripheral 61 172 35% (28–43) 14 104 14% (8–22)
Cancer cases with unspecified histology or localization are not shown.
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DNA chromatin changes could be detected in hundreds or
thousands of epithelial cells in sputum from cancer patients;
frankly malignant cells are not required to detect the disease.
Consequently, induction specimens that do not contain the
guarantee of quality by the presence of macrophages may yet
contain enough bronchial epithelial cells to produce a valu-
able score. This point is demonstrated by the fact that Lung-
Sign overall performance was comparable for cytology-inad-
equate versus adequate specimens.
One of the advantages of sputum analysis using a
biomarker approach in contrast to sputum cytology is that the
operating performance point of the test is adjustable. This
property makes it possible to optimize the performance of the
test for use in conjunction with standard methods used in
early lung cancer detection. There have been two suggested
roles for such biomarker tests to support early detection using
CT and bronchoscopy: before19,30 and after30 diagnostic
workup.
As a prescreener, a biomarker test would be employed
at a low specificity/high sensitivity threshold to find a higher
risk population suitable for CT screening. The test would
eliminate a significant number of unproductive CTs with as
few as possible false negatives. McWilliams et al.19 devel-
oped a simple sputum cytometry measure using the observa-
tion of five hyperdiploid nuclei (DI 1.2) in a specimen,
which they referred to as atypia, as an indication for more
intensive follow-up. In their study, the measure detected 13 of
14 cancers with a specificity of 25% for the 547 negative
subjects. Although the number of cancers in their study was
small, the result suggests that the detection of DNA atypia
alone, when applied to a screening population, may be able to
eliminate a significant fraction of unproductive CT scans.
As the resolution of CT scanners improves, more and
more nodules of undetermined significance are being found.
More than half of patients will be found to have nodules,31
and many of these nodules will require follow-up consisting
of biopsy or repeated CT scans over a 2-year period. In a
Mayo Clinic trial, only 7.1% of prevalence scan nodules 4
mm were found to be malignant. Biomarker tests can be used
to find a higher risk subset of patients among those found
with nodules of insufficient size to be immediately action-
able. As seen in Figure 3A, subjects with high LungSign
scores are at a significantly elevated risk of harboring lung
cancer. A high score for patients with indeterminate nodules
by CT may potentially be used to identify those who should
be sent for follow-on investigations more quickly. Alterna-
tively, low scores could help to reduce the anxiety of those
who are less likely to harbor a malignancy during the period
in which nodule growth is being assessed.
In conclusion, the measurement of nuclear chromatin
features through fully automated DNA cytometry may be a
valuable tool for the detection of lung cancer in high-risk
individuals. The LungSign test was able to resolve lung
cancers from negatives in a difficult context—a diagnostic
population with 33% disease prevalence. To our knowledge,
the validation trial, comprising analyzable sputum specimens
from 330 lung cancer patients, represents the largest lung
cancer population studied prospectively with a cytometric
FIGURE 4. Receiver operating characteristic curve compari-
sons of overall LungSign and conventional cytology perfor-
mance for early (stage 0/I) cancer versus nonearly (stage
II) cancer (A), adenocarcinoma versus squamous cell carci-
noma (B), and peripheral versus central localization (C).
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test. Although the trial protocol measured the performance of
a single application of LungSign, alone, it is the test’s
performance in conjunction with CT that is of interest. Com-
menting on the recent exciting results from the ELCAP CT
trial,32 Michael Unger3 wrote that although no single test has
the ability “to provide unequivocal information about the
biology of the tumor. . .the combination of molecular and
radiographic approaches can enrich the information on which
physicians base their decisions.” LungSign, as a continuous
measure of abnormality that is sensitive for early-stage can-
cer, may provide clinicians with additional information to
help guide their management decisions.
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